Precision Oncology
Individual Treatments for Individual Cancers
With your help, we are prepared to launch a new era in cancer care, delivering highly tailored treatments and risk-reduction strategies to patients based on their biology and the unique molecular characteristics of their tumor.
What Is Precision Oncology?
Every patient and their cancer contain a multitude of data points that can offer a plan for stopping that specific tumor in its tracks. Until recently, making sense of this molecular data was too expensive and too time-consuming.
Now, thanks to significant advances in our ability to gather and interpret that data, we are on the cusp of leveraging it to personalize therapies for each patient. That is the power of precision oncology: Rather than simply treat a patient’s cancer based on its primary site — whether liver or lung or breast or colon — we will soon be able to use its own biology against it.
We need your help to take the next leap forward. Fred Hutch scientists are making new discoveries every day, from how cancer cells metabolize certain nutrients to methods for targeting proteins expressed by those cells. But fully harnessing the power of precision medicine will require transformational investment that empowers our teams to dream bigger and push the boundaries of what’s possible.
The Power of Precision Oncology
Quickly matching drugs to patients with multiple myeloma
Multiple myeloma has more than five dozen mutations with variable drug responses, making it extremely difficult to treat. Fred Hutch researchers have shown that it’s possible to quickly test patients’ tumor cells against more than 150 drugs in the lab to determine which will be most effective.
Turning a weakness into a strength for lung cancer treatment
Our researchers have identified duplicate genes — which typically aid cancer by providing a backup if one gene dies — as a potential target for cancer drugs in patients with lung cancer.
Narrowing in on a target for prostate cancer treatment
Fred Hutch researchers have shown that some prostate cancer cells have high levels of a specific protein marker and using this marker to guide chemotherapy to these cancer cells could be an effective treatment.
Improving screening for esophageal cancer
We are much closer to understanding why some patients with a precancerous condition called Barrett’s esophagus progress to esophageal cancer, opening the possibility of future screening options that could identify who should be treated and who can just be monitored.
Featured Researchers
Dr. Eric Holland
Dr. Holland is a world-renowned physician-scientist who combines compassionate patient care with exacting laboratory research to discover more effective treatments for brain tumors.
Dr. Alice Berger
Dr. Berger, who holds the Innovators Network Endowed Chair, bridges laboratory studies and computational biology to understand how different gene variants contribute to cancer development.
Dr. Evan Ya-Wen Yu
Dr. Yu is a medical oncologist who provides a personalized-medicine approach to test novel therapies and discover unique cancer biomarkers for patients with prostate, bladder and testicular cancer.
Dr. Sita Kugel
Dr. Kugel works to understand the molecular changes that underpin different subtypes of pancreatic and liver cancer and how those molecular changes could be exploited to develop new targeted therapies.